Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial. This is an ASCO Meeting ...

OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative ...

First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer—What Happened?

Risk factors, clinical characteristics, and treatment outcomes for hepatocellular carcinoma in Rwanda. Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo ...

Glioblastoma is the most common and most aggressive form of primary brain tumor in adults and contributes to high social and medical burden as a result of its incurable nature and significant ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Although renal medullary carcinoma (RMC) is a rare subtype of kidney cancer, it is particularly devastating in that it is nearly uniformly lethal. No established guidelines exist for the diagnosis and ...

International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma Innate and adaptive immune system cells play a major ...

The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study. This is an ASCO Meeting ...

The integration of artificial intelligence (AI) into health care promises transformative advancements in diagnostics, treatment, and operational efficiency. However, this transformation introduces ...

Prognostic characteristics of patients with benign mesenteric lymph node enlargement after surgical resection for colorectal cancer. Sex differences in efficacy and toxicity of first-line treatment of ...

PURPOSE: Variable uptake of the glucose analog 18 fluorodeoxyglucose (FDG) has been noticed in positron emission tomography (PET) studies of breast cancer patients, with low uptake occurring ...